Related Experiment Videos
HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented
M Bauer1, H Wagner, G B Lipford
1Institute of Medical Microbiology, Immunology and Hygiene, Munich, Germany.
Immunology Letters
|March 10, 2000
Summary
Researchers identified a specific peptide from Human Papillomavirus type 16 (HPV-16) E7 protein that can induce T-cell responses. However, this peptide was not recognized by T-cells in HPV-16 infected cells, limiting its immunotherapy potential.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Human papillomaviruses (HPV), particularly HPV-16, are linked to cervical cancer development.
- HPV-16 E6 and E7 oncoproteins are frequently found in cervical carcinoma cells and are potential targets for immunotherapy.
Purpose of the Study:
- To identify and evaluate peptides derived from the HPV-16 E7 protein for their ability to induce T-cell responses against HLA-A2 positive cancer cells.
- To assess the immunogenicity and potential of these peptides for T-cell mediated immunotherapy.
Main Methods:
- Screening of HPV-16 E7-derived peptides for binding to HLA-A2.
- Testing immunogenicity and induction of specific cytotoxic T lymphocyte (CTL) responses in HLA-A2/H2-Kb transgenic mice.
- Assessing CTL activity against peptide-pulsed target cells and cells expressing E7 protein.
Main Results:
- Four out of eight screened peptides bound to HLA-A2.
- Peptide 86-93 induced CTL responses in HLA-A2/H2-Kb mice, which lysed targets presenting the peptide.
- However, induced CTLs did not target cells expressing the E7 protein, and E7 protein vaccination did not induce peptide 86-93 specific CTLs.
Conclusions:
- Peptide 86-93 binds to HLA-A2 and can elicit specific CTL responses in a relevant mouse model.
- The lack of CTL activity against E7-expressing cells suggests that peptide 86-93 is not processed or presented by HPV-16 infected cells, limiting its direct therapeutic application.